GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
V

Virpax Pharmaceuticals VRPX · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Virpax Pharmaceuticals — daily VRPX Delayed
Market value
$1,280
Last close × shares
Volume
212
Shares, 9 Nov 2026

About Virpax Pharmaceuticals

Its shares trade under the ticker VRPX. It has been listed since 17 February 2021.

Virpax Pharmaceuticals, Inc. is a preclinical stage biopharmaceutical company, which engages in the development of branded, non-addictive pain management products. The company is headquartered in Berwyn, Pennsylvania. The company went IPO on 2021-02-17. The firm is focused on developing novel and drug delivery systems. Its drug-delivery systems and drug-releasing technologies being developed are focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system (CNS) disorders to enhance patients’ quality of life. Its portfolio consists of multiple preclinical stage product candidates: Epoladerm, Probudur, Envelta, PES200, AnQlar and NobrXiol. Probudur is a drug product candidate based on a liposomal delivery system utilizing large multi-vesicular vesicles (LMVVs) encapsulating a high dose of the local anesthetic bupivacaine. PES200 enables the delivery of a metabolically labile peptide drug (Enkephalin) into the brain for post-traumatic stress disorder. NobrXiol is being developed by Nanomerics as an investigational formulation delivered via the nasal route to enhance Cannabidiol transport to the brain.

Figures and description from our data supplier, not checked against the company's own report.

More about Virpax Pharmaceuticals →

Latest on Virpax Pharmaceuticals

Our reporting

We have not reported on Virpax Pharmaceuticals yet.

Next results

19 Nov 2026

Due on 19 Nov 2026.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Virpax Pharmaceuticals's ticker?

Virpax Pharmaceuticals trades as VRPX on its US listing, under ISIN US9282513053.

What was Virpax Pharmaceuticals's last closing price?

0.00 on 9 Nov 2026. The figure is in USD and is never converted.

When does Virpax Pharmaceuticals next report results?

Results are expected on 19 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.